Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: Saving costs at what expense?
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2017
Price : $35 *
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms DRESS
- 12 Jun 2017 3-year long term data (results from the extension phase of the study, n=172) published in the Annals of the Rheumatic Diseases.
- 22 Jul 2015 Status changed from active, no longer recruiting to completed.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.